- Home
- PCT vs ELVN Comparison
PCT vs ELVN Comparison
Compare PCT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCT | ELVN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | 174 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCT | ELVN |
|---|---|---|
| Price | $8.63 | $44.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.00 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 6.3M | 1.5M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $380.44 | N/A |
| Revenue Next Year | $203.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $14.79 |
| 52 Week High | $17.37 | $48.53 |
Technical Indicators
Market Signals| Indicator | PCT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 59.81 |
| Support Level | $7.87 | $17.90 |
| Resistance Level | $9.56 | $48.53 |
| Average True Range (ATR) | 1.00 | 3.14 |
| MACD | -0.64 | 0.88 |
| Stochastic Oscillator | 10.11 | 79.15 |
Price Performance
Historical ComparisonAbout PCT PureCycle Technologies Inc.
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.